Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of
this trial is to compare the efficacy and safety of NN5401 (insulin degludec/insulin aspart
(IDegAsp)) with insulin glargine (IGlar), both as add-on to subject's ongoing treatment with
metformin + at least one OAD (oral anti-diabetic drug).
The main period is registered internally at Novo Nordisk as NN5401-3590 while the extension
period is registered as NN5401-3726.